Aspirin or heparin injections to prevent blood clots after hip fracture
Compares aspirin tablets with heparin injections for preventing blood clots after hip fracture.
Key facts
- Who runs it
- Queen Mary University of London
- Where
- United Kingdom1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Delivery and Implementation of a Randomised Crossover Trial on Thrombosis
- Status
- Recruiting
- People taking part
- 21,194 people, planned
- Started
- 1 Jul 2026
- Expected to end
- 30 Apr 2028
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Patients in hospitals allocated to this arm will receive aspirin as their routine thromboprophylaxis after surgery.
- Low molecular weight heparin (LMWH)
- Record updated
- 23 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 60 or older who have a fragility hip fracture (a hip broken in a minor fall or injury). It compares aspirin tablets with low molecular weight heparin (LMWH) injections for preventing blood clots after hip surgery.
- Age
- 60 to 150 years in the criteria (the record also lists 60 Years to 120 Years)
- Sex
- All sexes
- Disease stage
- Fragility hip fracture, recorded in the UK hip fracture registries (NHFD and SHFA).
Main reasons for not taking part
- People who cannot be entered in the NHFD and SHFA hip fracture registries
- People with a hip fracture who are above 150 years of age
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- Adults from 60 to 150 years sustaining fragility hip fracture identified by their entry into UK hip registries
Who cannot take part
- Individuals who do not meet the eligibility criteria to be enrolled in the NHFD and SHFA registries Hip fracture individuals above 150 years of age
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 60 and 120 years old?
This trial is currently available in United Kingdom.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
What is the Study About? The DIRECT study (Delivery and Implementation of a Randomised Crossover Trial on Thrombosis) is a large research project investigating the best way to prevent blood clots (thrombosis) in people who break their hip. The study will compare two common treatments: aspirin (a tablet) and low molecular weight heparin (LMWH, an injection).
Read full original descriptionShow less
Every year, thousands of people in the UK suffer a hip fracture, which often requires surgery and hospital care. After a hip fracture, patients are at risk of developing serious blood clots in their legs (deep vein thrombosis, DVT) or lungs (pulmonary embolism, PE), which can be life-threatening. Currently, doctors prescribe different medications to prevent these clots, but there is uncertainty about which treatment is best for people with hip fractures.
Why is This Study Needed? Blood clot prevention is vital for hip fracture patients, but the current recommended treatment (LMWH) involves daily injections for 28 days, which some patients find uncomfortable and difficult to manage at home. Aspirin, a tablet taken by mouth, is a much simpler alternative, but there is not enough evidence to confirm whether it is as effective and safe as LMWH in this group of patients.
The DIRECT study will help doctors and the NHS understand whether aspirin could be a safe and cost-effective alternative to LMWH. If aspirin is found to be just as effective, it could make treatment easier for patients and save millions of pounds for the NHS.
How Will the Study Work? The study will involve 96 hospitals across the UK and will include over 21,000 patients aged 60 and older who have broken their hip. Hospitals will be randomly assigned to use either aspirin or LMWH as their standard treatment for a set period. After this, they will switch to the other treatment. This approach allows researchers to compare the two treatments fairly.
All data will be collected from national NHS databases, which routinely record patient care and outcomes. This means patients will not need to do anything extra or attend additional follow-ups.
What Are the Expected Benefits?
This study will provide clear evidence on which treatment is better for preventing blood clots while minimising risks like bleeding. If aspirin is shown to be as effective as LMWH, it could:
* Reduce the need for daily injections, making treatment more comfortable for patients. * Lower NHS costs, as aspirin is much cheaper than LMWH. * Provide a simple, widely available treatment option for older adults with hip fractures.
How Will Patient Data Be Protected? The study will use anonymised patient data from NHS records. This means that all personal details will be kept confidential and protected according to strict NHS and research regulations. Patients who do not want their data to be used can opt out via NHS data-sharing policies.
Summary The DIRECT study is an important project that will help improve care for hip fracture patients by determining whether aspirin can be a safe and effective alternative to injections for preventing blood clots. The results will help shape future NHS guidelines, ensuring patients receive the best possible treatment while reducing unnecessary costs and discomfort.
The 2 groups in the trial
- Aspirin ArmTreatment being tested
Patients in hospitals allocated to this arm will receive aspirin as their routine thromboprophylaxis after surgery. Aspirin is a widely available, low-cost medication that may reduce the risk of blood clots with fewer side effects such as bleeding.
Treatment: Patients in hospitals allocated to this arm will receive aspirin as their routine thromboprophylaxis after surgery.
- Low Molecular Weight Heparin (LMWH) ArmExisting treatment, for comparison
Patients in hospitals allocated to this arm will receive LMWH, which is the current standard treatment in many hospitals for preventing blood clots after hip surgery.
Treatment: Low molecular weight heparin (LMWH)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Delivery and Implementation of a Randomised Cluster Crossover Trial on Thrombosis
- Plain-language title
- Aspirin or heparin injections to prevent blood clots after hip fractureGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Criteria questions
- Built from NCT06937372, who can take part
- Record updated
- 23 September 2026